Hemoglobin >= 8 g/dL, within 2 weeks of randomization
Within 6 weeks prior to randomization: Hemoglobin must be >= 10 g/dL
Hemoglobin > 9 g/dL, obtained within 4 weeks prior to randomization
Hemoglobin >= 10.0 g/dL measured within 28 days prior to randomization
Obtained within 28 days prior randomization: hemoglobin must be >= 8 g/dL
Hemoglobin >= 9.0 g/dL, within 4 weeks of randomization
Hemoglobin >= 10.0 g/dL and no known active bleeding, measured within 28 days prior to administration of study treatment
Within 10 days of treatment initiation: Hemoglobin >= 8 g/dL
Preoperative hemoglobin concentration >= 10 mg/dL within 30 days of registration
Hemoglobin >= 9 g/dL (for treatment phase)
Hemoglobin >= 9.0 g/dL must be met within 28 days of C1D1
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin) AND
Hemoglobin >= 9.0 gr/dL
Hemoglobin ?8 g/dL (?80 g/L) (superficial tumor dosing only)
Documented within 14 days of registration: Hemoglobin >= 8 g/dL (may be supported)
Hemoglobin >= 8.0 g/dL at least 3 weeks prior to screening unless attributable to disease
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin)
Hemoglobin > 9 g/dL (standard international [SI] units: 90 g/L)
Hemoglobin >= 9 g/dL, within 16 days of starting therapy
Hemoglobin >= 9.0 g/dL within 14 days prior to first dose of protocol-indicated treatment.
Within 14 days of randomization: Hemoglobin >= 10 g/dL
Within 14 days of the first dose of study drug: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.5 g/dL, performed within 14 days prior to day 1 of protocol therapy
Hemoglobin concentration ? 9.0 g/dL.
Within 28 days prior to treatment start: Hemoglobin >= 9 g/dL
Hemoglobin >= 9.0 g / dl obtained =< 14 days prior to study initiation
Obtained within 21 days prior to cycle 1, day 1: hemoglobin >= 10 g/dl
Within 28 days of cycle 1 day 1: Hemoglobin\t>= 8 g/dL
STUDY TREATMENT: Hemoglobin >= 9.0 g/dL within 14 days prior to the first study treatment.
Hemoglobin >= 9.0 g/dL within 90 days prior to randomization
Hemoglobin >= 8 g/dL (may be supported), within 14 days of registration and within 7 days of the start of treatment
Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
Hemoglobin ? 8 g/dL within 14 days of treatment initiation
Hemoglobin > 8 g/dL (may be supported)
Hemoglobin > 8.0 mg/dL within 14 days of treatment initiation
Hemoglobin >= 9.0 g/dL, obtained within 7 days prior to first study treatment
Within 14 days of the first dose of the study drugs: Hemoglobin >= 9 g/dl (treatment allowed).
Hemoglobin ? 8 g/dL within 10 days prior to “on study” status
Within 7 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL (unless due to bone marrow infiltration by tumor, in which case hemoglobin >= 8 g/dL is allowed) and no blood transfusions in the 7 days prior to entry.
Within 28 days prior to enrollment: Hemoglobin >= 9 g/dL
Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
Patient has a hemoglobin value <10 g/dL at Screening
Within 7 days (+ 3 day window) of enrollment: Hemoglobin >= 9.0 g/dL
Within 7 days before the first dose of study treatment: Hemoglobin >= 9 g/dL
Hemoglobin >= 9 g/dL results within 7 days before study drug administration
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): hemoglobin >= 9.0 g/dL
Hemoglobin (Hg) >= 9 g/dl
Hemoglobin >= 9.0 g/dL within 14 days prior to first dose
Obtained within 14 days of randomization: Hemoglobin >= 9.0 g/dL
Determined within 3 weeks of treatment initiation: Hemoglobin >= 8.0 g/dl
Hemoglobin >= 9 g/dL (within 16 days of enrollment)
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
Hemoglobin >= 9 g/dl (treatment allowed) within 14 days prior to study entry
Hemoglobin ? 9.0 g/dL within 14 days prior to the first study treatment (cycle 1, day 1)
To be performed within 10 business days prior to day 1: Hemoglobin >= 8.5 g/dL
Hemoglobin >= 8 g/dL within 16 days of treatment initiation
Obtained =< 14 days prior to randomization: Hemoglobin >= 9.0 g/dL
Completed within 60 days of surgery: Hemoglobin ? 9.0 g/dL
Within 14 days of first dose of study drug administration: Hemoglobin >= 9.0g/dl
Hemoglobin >= 10 gr/dL
Hemoglobin < 10 gr/dL
Hemoglobin > 9 g/dL (untransfused)
Must be met within 28 days of C1D1: Hemoglobin >= 9.0 g/dl
Hemoglobin >= 8 g/dL; this value must be obtained within four weeks before protocol entry
1.0 g/dL,
Hemoglobin > 9 g/dL during screening evaluation
Within 14 days prior to randomization: Hemoglobin must be >= 8 g/dL
Within 14 days of first dose of study drug: Hemoglobin >= 9 g/dL
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL.
Hemoglobin >/= 9 g/dL prior to initial treatment
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Heme: Plt Ct ? 100 x 103/µL, ANC ? 1.5 x 103/µL, and Hemoglobin ? 9 g/dL
Hemoglobin >= 8 g/dL within 2 weeks of the initiation of treatment
Hemoglobin must be >= 10 g/dL within 28 days before randomization
If patient will need ribavirin in their regimen then the following inclusion:\r\n* Hemoglobin (Hg) > 12 g/dL for male\r\n* Hg > 11 g/dL for female
Hemoglobin >= 9 g/dL, within 2 weeks of the first dose of study treatment
Hemoglobin >= 10.0 g/dL, measured within 28 days prior to administration of study treatment
Hemoglobin >= 9 g/dl (per manufacturer recommendation)
Hemoglobin >= 11 g/dL within four weeks prior to randomization
For CRC, hemoglobin ?9.0 g/dL
Patients must have a serum erythropoietin level documented before randomization and =< 56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time that serum erythropoietin is drawn
Within 14 days of enrollment: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin); AND
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
Patient has screening hemoglobin <10 mg/dL.
Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
Within 4 weeks of administration of study therapy: Hemoglobin >= 9 g/dL
Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)
Hemoglobin >= 9.0 g/dL (hemoglobin may be supported by transfusion) obtained =<14 days prior to randomization
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); hemoglobin ? 9.0 g/dL
Hemoglobin >= 9.0 g/dL obtained =< 14 days prior to randomization
Hemoglobin (Hg) >= 9 g/dL
Hemoglobin >= 9.0 g/dL (obtained within 14 days prior to the first study treatment [course 1, day 1])
Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
Hemoglobin >= 9.0 mg/ml
Within 14 days prior to first study treatment: Hemoglobin >= 9.0 g/dL
Hemoglobin >= 8.0 g/dL obtained at baseline (day 1 of cycle 1, before study drug administration)
Hemoglobin >= 8 g/dL, within 14 days prior to initiation of study drug
Hemoglobin ? 8 g/dL (80 g/L) within 21 days prior to randomization
Hemoglobin (Hg) >= 9.0 mg/dL
Hemoglobin >= 9.0 g/dL (SI units 90 g/L)
Obtained within 14 days prior to initiation of treatment: Hemoglobin >= 8.0 g/ dL
Hemoglobin >= 9.0 g/dL, obtained within 14 days of the first dose of study drug
Hemoglobin level less than or equal to 11.0 g/dL as assessed by the local laboratory; sample obtained within 7 days prior to randomization (retest in screening is acceptable).
Hemoglobin >= 9.0 g/dL within 90 days before enrollment
Hemoglobin >= 9 g/dL, obtained within 14 days prior to treatment start
Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL
Hemoglobin >= 12 mg/dL for men and >= 11 for women
Hemoglobin ? 8.0 g/dL (? 7.0 g/dL for hematologic malignancy) Renal function
Hemoglobin >= 9.0 g/dL, performed within 10 days of protocol enrollment
Severe infections within 4 weeks prior to Cycle 1, Day 1
Severe infection within 4 weeks prior to enrollment
Severe infections within 4 weeks prior to enrollment;
Severe infection within 4 weeks prior to enrollment
Severe infection within 4 weeks prior to D1 of C1
Severe infections at the time of randomization
Severe infections within 4 weeks prior to randomization
Severe infections within 4 weeks prior to Cycle 1, Day 1
Severe infections within 4 weeks prior to Cycle 1 Day 1
Patients with severe systemic infections
Severe infections within 28 days prior to the first dose of study treatment
Severe systemic infections, current or within the two weeks prior to initiation of AEB071.
Severe infections within 4 weeks prior to Cycle 1, Day 1
Recent infections not meeting the criteria for severe infections within 2 weeks prior to Cycle 1, Day 1
Severe infections within 4 weeks prior to Day 1